Literature DB >> 25465643

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis.

James Walter1, Lorraine B Ware2, Michael A Matthay3.   

Abstract

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25465643     DOI: 10.1016/S2213-2600(14)70217-6

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  104 in total

1.  Mesenchymal Stromal Cells Deficient in Autophagy Proteins Are Susceptible to Oxidative Injury and Mitochondrial Dysfunction.

Authors:  Sailaja Ghanta; Konstantin Tsoyi; Xiaoli Liu; Kiichi Nakahira; Bonna Ith; Anna A Coronata; Laura E Fredenburgh; Joshua A Englert; Claude A Piantadosi; Augustine M K Choi; Mark A Perrella
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

2.  Expression of Stromal Cell-Derived Factor-1 by Mesenchymal Stromal Cells Impacts Neutrophil Function During Sepsis.

Authors:  Min-Young Kwon; Sailaja Ghanta; Julie Ng; Konstantin Tsoyi; James A Lederer; Roderick T Bronson; Souheil El-Chemaly; Su Wol Chung; Xiaoli Liu; Mark A Perrella
Journal:  Crit Care Med       Date:  2020-05       Impact factor: 7.598

3.  Cell therapy for acute respiratory distress syndrome patients: the START study.

Authors:  Fernanda Ferreira Cruz; Patricia Rieken Macedo Rocco
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 4.  Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease.

Authors:  Airan Liu; Xiwen Zhang; Hongli He; Li Zhou; Yoshifumi Naito; Shinji Sugita; Jae-Woo Lee
Journal:  Expert Opin Biol Ther       Date:  2019-11-18       Impact factor: 4.388

Review 5.  The intensive care medicine research agenda on septic shock.

Authors:  Anders Perner; Anthony C Gordon; Derek C Angus; Francois Lamontagne; Flavia Machado; James A Russell; Jean-Francois Timsit; John C Marshall; John Myburgh; Manu Shankar-Hari; Mervyn Singer
Journal:  Intensive Care Med       Date:  2017-05-12       Impact factor: 17.440

Review 6.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

7.  Umbilical Cord Blood Mesenchymal Stem Cells Enhance Lipopolysaccharide-Induced IL-10 and IL-37 Production in THP-1 Cells.

Authors:  Ting Zhou; Yan Sun; Yanli Wang; Xiaobing Chen; Luo Zhuo; Lin Bu; Suo Xu; Jiayan Han; Xiaomin Li; Jiaxin Shi
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

8.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Authors:  Michael A Matthay; Carolyn S Calfee; Hanjing Zhuo; B Taylor Thompson; Jennifer G Wilson; Joseph E Levitt; Angela J Rogers; Jeffrey E Gotts; Jeanine P Wiener-Kronish; Ednan K Bajwa; Michael P Donahoe; Bryan J McVerry; Luis A Ortiz; Matthew Exline; John W Christman; Jason Abbott; Kevin L Delucchi; Lizette Caballero; Melanie McMillan; David H McKenna; Kathleen D Liu
Journal:  Lancet Respir Med       Date:  2018-11-16       Impact factor: 30.700

9.  Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo.

Authors:  Michael C W Chan; Denise I T Kuok; Connie Y H Leung; Kenrie P Y Hui; Sophie A Valkenburg; Eric H Y Lau; John M Nicholls; Xiaohui Fang; Yi Guan; Jae W Lee; Renee W Y Chan; Robert G Webster; Michael A Matthay; J S Malik Peiris
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

Review 10.  Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.

Authors:  Hong-Long Ji; Cong Liu; Run-Zhen Zhao
Journal:  World J Stem Cells       Date:  2020-06-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.